Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients

被引：0
|
作者：
Baroncini, D.
Ghezzi, A.
Rocca, M. A.
Annovazzi, P. O.
Bianchi, A.
Minonzio, G.
Zaffaroni, M.
Filippi, M.
Comi, G.
机构：
[1] Ctr Studi Sclerosi Multipla, Gallarate, Italy
[2] Hosp San Raffaele, I-20132 Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：219 / 220
页数：2
相关论文
共 50 条
  • [31] Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation
    Croteau, David
    Tobenkin, Anne
    Brinker, Allen
    Kortepeter, Cindy M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (06) : 903 - 912
  • [32] Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
    Abbadessa, Gianmarco
    Maida, Elisabetta
    Miele, Giuseppina
    Bile, Floriana
    Lavorgna, Luigi
    Bonavita, Simona
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [33] Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis
    Sato, Kazunori
    Niino, Masaaki
    Kawashima, Atsushi
    Yamada, Moemi
    Miyazaki, Yusei
    Fukazawa, Toshiyuki
    INTERNAL MEDICINE, 2018, 57 (18) : 2647 - 2655
  • [34] Severe Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review
    Huppke, Brenda
    de Vries, Heike
    Blaschek, Astrid
    Huppke, Peter
    NEUROPEDIATRICS, 2025, 56 (02) : 147 - 150
  • [35] Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
    Bsteh, Gabriel
    Hegen, Harald
    Riedl, Katharina
    Altmann, Patrick
    Auer, Michael
    Berek, Klaus
    Di Pauli, Franziska
    Ehling, Rainer
    Kornek, Barbara
    Monschein, Tobias
    Rinner, Walter
    Schmied, Christiane
    Wurth, Sebastian
    Zebenholzer, Karin
    Zinganell, Anne
    Zrzavy, Tobias
    Zulehner, Gudrun
    Deisenhammer, Florian
    Rommer, Paulus
    Leutmezer, Fritz
    Berger, Thomas
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (05) : 1609 - 1616
  • [36] Withdrawal Rebound after Fingolimod in Multiple Sclerosis Patients
    Gunduz, Tuncay
    Kurtuncu, Murat
    Eraksoy, Mefkure
    NEUROLOGY, 2016, 86
  • [37] Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report
    Baghbanian, Seyed Mohammad
    Amiri, Mohammad Reza Mahdavi
    NEUROLOGICAL SCIENCES, 2021, 42 (03) : 1175 - 1177
  • [38] Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
    Hersh, Carrie M.
    Harris, Haleigh
    Ayers, Malissa
    Conway, Devon
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (04)
  • [39] Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
    Daelman, L.
    Maitrot, A.
    Maarouf, A.
    Chaunu, M. P.
    Papeix, C.
    Tourbah, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1647 - 1649
  • [40] Fingolimod discontinuation restores cardiovagal gain in patients with relapsing-remitting multiple sclerosis
    Roy, S.
    Wang, R.
    Liu, M.
    Leal, C. de Rojas
    Lee, D. -H.
    Linker, R. A.
    Hilz, M. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 533 - 533
12345